|1.||Kontoghiorghes, George J: 29 articles (03/2015 - 01/2002)|
|2.||Kolnagou, Annita: 18 articles (01/2015 - 01/2002)|
|3.||Galanello, Renzo: 18 articles (06/2014 - 09/2002)|
|4.||Piga, Antonio: 15 articles (07/2013 - 09/2002)|
|5.||Maggio, Aurelio: 11 articles (07/2015 - 03/2002)|
|6.||Prossomariti, Luciano: 10 articles (08/2013 - 03/2006)|
|7.||Tricta, Fernando: 9 articles (10/2014 - 05/2003)|
|8.||Fucharoen, Suthat: 8 articles (05/2015 - 01/2006)|
|9.||Peng, Ching-Tien: 8 articles (07/2014 - 01/2006)|
|10.||Cianciulli, Paolo: 8 articles (08/2013 - 03/2002)|
11/01/2010 - "This study evaluated the safety and efficacy of a new liquid formulation of deferiprone for the treatment of transfusional iron overload in children 1-10 years old. "
11/01/2010 - "The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload."
11/01/2010 - "The results of this study show a favorable benefit/risk ratio of deferiprone oral solution for the treatment of young children with transfusional iron overload."
03/01/2010 - "The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic and/or oncologic patients with a high iron overload. "
02/01/1997 - "Clinical trials are in progress in many centers worldwide that will provide further information on the long-term effectiveness of deferiprone as well as on the incidence of serious adverse effects in patients with iron overload. "
|2.||beta-Thalassemia (Cooley's Anemia)
03/01/2006 - "Oral deferiprone (L1) appears to be promising in the treatment of beta-thalassemia major (TM) patients. "
03/01/2006 - "Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*."
01/01/2006 - "A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong."
04/01/2008 - "Our objective was to assess the long-term efficacy of deferiprone in patients with thalassemia major. "
09/01/2003 - "Based on our findings in a 1-year multicenter, prospective study of the safety and efficacy of deferiprone in patients with thalassemia major, we have extended the treatment period to 4 years. "
04/01/2013 - "Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited to a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study of deferiprone to determine its clinical efficacy and safety. "
12/01/2012 - "The method was successfully applied to a pharmacokinetic study of deferiprone in six thalassemia patients."
04/01/1990 - "Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients."
12/01/2013 - "Routine radiographs of left wrist and hand done for bone age estimation in 40 children with thalassemia were evaluated and revealed unique radiographic changes in 13 children (10 males: 3 females) with previous or current deferiprone related arthropathy. "
12/01/2013 - "Distal ulnar changes in children with thalassemia and deferiprone related arthropathy."
01/01/2009 - "Therapy combining deferiprone with DFO has proved effective in the management of severe cardiac siderosis. "
01/01/2013 - "Further studies are required to assess the clinical efficacy of deferiprone in superficial siderosis. "
01/01/2012 - "Prospectively designed efficacy studies are necessary to determine the clinical efficacy of deferiprone in superficial siderosis."
01/01/2012 - "Pilot safety trial of deferiprone in 10 subjects with superficial siderosis."
01/01/2013 - "The proposed deferiprone-based therapy has provided a paradigm for treating regional types of siderosis without affecting hematological parameters and systemic functions. "
07/01/2007 - "A 6-month treatment with 20 to 30 mg/kg/d deferiprone of 9 adolescent patients with no overt cardiomyopathy reduced R2* from 18.3 s(-1) (+/- 1.6 s(-1)) to 15.7 s(-1) (+/- 0.7 s(-1); P < .002), specifically in dentate nuclei and proportionally to the initial R2* (r = 0.90). "
01/01/1997 - "Patients with cardiomyopathy due to iron overload should be given intravenous DFX rather than deferiprone. "
01/01/2008 - "Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone."
01/01/2006 - "The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination. "
01/01/2006 - "Combination therapy with deferoxamine and deferiprone has been shown to be more effective than either drug used alone in patients with beta-thalassemia major and symptomatic cardiomyopathy. "
|8.||Iron Chelating Agents
|1.||Chelation Therapy (Therapy, Chelation)
|3.||Complementary Therapies (Alternative Medicine)
|4.||Blood Transfusion (Blood Transfusions)